RECIST 1.1—Update and clarification: From the RECIST committee

Schwartz, Lawrence H.; Litière, Saskia; Vries, Elisabeth G.E. de; Ford, Robert; Gwyther, Stephen J.; Mandrekar, Sumithra J.; Shankar, Lalitha; Bogaerts, Jan; Chen, Alice; Dancey, Janet; Hayes, Wendy; Hodi, F. Stephen; Hoekstra, Otto S.; Huang, Erich P.; Lin, Nancy U.; Liu, Yan; Therasse, Patrick; Wolchok, Jedd D.; Seymour, Lesley

doi:10.1016/j.ejca.2016.03.081

Cited by 1,394 publications

(1,112 citation statements)

References 6 publications

Supporting

Mentioning

999

Contrasting

Unclassified

Order By: Relevance

“…Response evaluation was done using RECIST version 1.1 [20]. After radiotherapy progressive disease was diagnosed only if the tumor progressed outside the radiation field.…”

Section: Response and Toxicitymentioning

confidence: 99%

Non-methylated MGMT as Predictive Factor in Newly Diagnosed Glioblastoma Multiforme Treated with Bevacizumab Concurrent with Radiotherapy Followed by Adjuvant Bevacizumab plus Irinotecan versus Temozolomide Concurrent with Radiotherapy Followed by Adjuvant Temozolomide

Mohamed¹,

Elkady²,

Shosha³

et al. 2018

Arch Cancer Re

View full text Add to dashboard Cite

Background and Purpose: Temozolomide is the standard treatment for patients with newly diagnosed glioblastoma multiform that had methylated O 6 -methylguanine-DNA methyltransferase promotor, but it had a limited efficacy in non-methylated MGMT. Thus the aim of this study is to compare bevacizumab plus irinotecan versus standard temozolomide in newly diagnosed non methylated MGMT glioblastome multiforme.

show abstract

“…Response evaluation was done using RECIST version 1.1 [20]. After radiotherapy progressive disease was diagnosed only if the tumor progressed outside the radiation field.…”

Section: Response and Toxicitymentioning

confidence: 99%

Non-methylated MGMT as Predictive Factor in Newly Diagnosed Glioblastoma Multiforme Treated with Bevacizumab Concurrent with Radiotherapy Followed by Adjuvant Bevacizumab plus Irinotecan versus Temozolomide Concurrent with Radiotherapy Followed by Adjuvant Temozolomide

Mohamed¹,

Elkady²,

Shosha³

et al. 2018

Arch Cancer Re

View full text Add to dashboard Cite

show abstract

“…Based on the aims of the traditional strategies, the Response Evaluation Criteria In Solid Tumors (RECIST) was published in February 2000, by an international collaboration including the European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group, and comprised a set of published rules that define when tumors in cancer patients improve (“respond”), stay the same (“stabilize”), or worsen (“progress”), during treatments. The majority of clinical trials evaluating cancer treatments for an objective response in solid tumors are using RECIST, of which the core criterion is the extent of eradicating the cancer cells and the primary focus [72]. …”

Section: Clinical Issues and Experiences Of Gene Therapymentioning

confidence: 99%

Historical and Clinical Experiences of Gene Therapy for Solid Cancers in China

Gao

Zhang

et al. 2017

Genes

View full text Add to dashboard Cite

Based on the theoretical and clinical development of modern medicines, gene therapy has been a promising treatment strategy for cancer and other diseases. The practice of gene therapy is nearly 27 years old, since the first authorized gene transfer study took place at the National Institute of Health in 1989. However, gene therapy was not readily adopted worldwide, until recently. Several gene therapy clinical trials have been carried out in China since 1998, and medical research in China has flourished. In this report, we review the history of gene therapy in China, focusing on treatment protocol, the administration cycle, dosage calculation, and the evaluation of therapeutic effects, in order to provide more information for the additional development of this promising treatment strategy.

show abstract

“…1,2 The current gold standard in the case of solid tumors is the RECIST. 3–5 RECIST was a guideline devised to standardize monitoring treatment based on imaging. The approach involves manually assessing differences in size of the target lesions on baseline and repeat CT scans (after therapy) to define various standardized categories 3,6 of treatment response.…”

mentioning

confidence: 99%

Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications

Bera

Velcheti

Madabhushi

2018

American Society of Clinical Oncology Educational Book

View full text Add to dashboard Cite

OVERVIEW The current standard of Response Evaluation Criteria in Solid Tumors (RECIST)–based tumor response evaluation is limited in its ability to accurately monitor treatment response. Radiomics, an approach involving computerized extraction of several quantitative imaging features, has shown promise in predicting as well as monitoring response to therapy. In this article, we provide a brief overview of radiomic approaches and the various analytical methods and techniques, specifically in the context of predicting and monitoring treatment response for non–small cell lung cancer (NSCLC). We briefly summarize some of the various types of radiomic features, including tumor shape and textural patterns, both within the tumor and within the adjacent tumor microenvironment. Additionally, we also discuss work in delta-radiomics or change in radiomic features (e.g., texture within the nodule) across longitudinally interspersed images in time for monitoring changes in therapy. We discuss the utility of these approaches for NSCLC, specifically the role of radiomics as a prognostic marker for treatment effectiveness and early therapy response, including chemoradiation, immunotherapy, and trimodality therapy.

show abstract

RECIST 1.1—Update and clarification: From the RECIST committee

Cited by 1,394 publications

References 6 publications

Non-methylated MGMT as Predictive Factor in Newly Diagnosed Glioblastoma Multiforme Treated with Bevacizumab Concurrent with Radiotherapy Followed by Adjuvant Bevacizumab plus Irinotecan versus Temozolomide Concurrent with Radiotherapy Followed by Adjuvant Temozolomide

Non-methylated MGMT as Predictive Factor in Newly Diagnosed Glioblastoma Multiforme Treated with Bevacizumab Concurrent with Radiotherapy Followed by Adjuvant Bevacizumab plus Irinotecan versus Temozolomide Concurrent with Radiotherapy Followed by Adjuvant Temozolomide

Historical and Clinical Experiences of Gene Therapy for Solid Cancers in China

Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications

Contact Info

Product

Resources

About